Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Immuron Surges On U.S. DoD Funding For Travelan Research

Published 01/12/2022, 09:57 AM
Updated 01/12/2022, 09:59 AM
© Reuters.

By Sam Boughedda

Investing.com — Immuron Ltd ADR (NASDAQ:IMRN) shares surged over 43% Wednesday on news of a A$6.2 million ($4.45m) award from the Defense Department to clinically evaluate a military strength dosing regimen for Travelan.

Immuron was awarded A$4.8 million ($3.43m) million funding by the Defense Department for Travelan, while the U.S Naval Medical Research Center received A$1.4 million ($1.02m) in funding to support the clinical development effort, bringing the total award to A$6.2 million.

Travelan is a diarrhea medication, with the funding being provided to test the efficacy of a single larger dose regimen in diarrhea caused by enterotoxigenic escherichia Coli. 

There are plans to run a controlled human infection model clinical trial in 60 healthy volunteers in the U.S.

“This new project expands our clinical development program and represents the first of several significant clinical trials which the Company expects to undertake with the US Military in 2022," said Dr. Jerry Kanellos, CEO of Immuron.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.